Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2024

Genmab — Marts 2024

Planlagt Fastgjort Låst Flyttet Genmab
830 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #41

    Jeg er meget tryg ved min investering i Genmab. Særligt med en P/E på 21 😉

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #42

      Lidt lavere rente og vi skal op i 30-35.

      1 Reply Last reply
      0
      • JørgenVarnæsJ Offline
        JørgenVarnæsJ Offline
        JørgenVarnæs
        wrote on sidst redigeret af
        #43

        Rente? Der skal tillid til at GEN kan smide penge på bunden. Den er der ikke nu

        1 Reply Last reply
        0
        • DarvinD Offline
          DarvinD Offline
          Darvin
          wrote on sidst redigeret af
          #44

          OG Genmab stiger såmænd 5,8% i US så man kan nyde vinen med en vis rimelighed i aften - god weekend

          1 Reply Last reply
          0
          • K Offline
            K Offline
            Klarussen
            wrote on sidst redigeret af
            #45

            Jeg investerer gerne igen når FA/TA viser en bedre retning. Kan være jeg ikke kommer med på bunden, men det er jeg helt tryg ved. Imens er der god indtjening andre steder. Helt enig pensionisten: "spredning er din redning". God weekend

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #46

              @US_FDA
              approves #Amivantamab WITH #CHEMOTHERAPY for #1stLine treatment of advanced non-small cell #LungCancer with #EGFR #Exon20 mutations.

              Approval based on #Papillion trial https://twitter.com/RManochakian/status/1763620782834418055

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #47

                "Amivantamab is a fully human bispecific antibody. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. (Janssen) to create and develop bispecific antibodies using Genmab's DuoBody® technology platform. Janssen is responsible for the development and commercialization of amivantamab".

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  peter12
                  wrote on sidst redigeret af
                  #48

                  Fra Onclive https://www.onclive.com/view/fda-approves-amivantamab-plus-chemo-for-egfr-exon-20-insertion-nsclc

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bikube
                    wrote on sidst redigeret af
                    #49

                    Hvor stor en del af lungekræft har EGFR20?

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      peter12
                      wrote on sidst redigeret af
                      #50

                      3% står der https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr/egfr-exon-20-insertion-mutation

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bikube
                        wrote on sidst redigeret af
                        #51

                        Tak Peter12 - 3% af rigtig mange er jo en hel del.

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #52

                          Fed stigning 5.5% op i US.

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #53

                            Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons https://www.proinvestor.com/investornyt/1126030/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #54

                              JNJ: RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #55

                                JNJ har udtalt at de går efter hele egfr markedet ved at tage markedsandele fra Tigresso (AstaZenaca), der omsætter for ca $6 bn årligt. De første data vi så for nylig i JNJs kombi forsøg, hvor Rybrevant var det ene stof, var ikke helt overbevisende/understøttende for at kunne nå det mål. Tigresso er ikke godkendt i exon 20 mutationen.

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bikube
                                  wrote on sidst redigeret af
                                  #56

                                  Så fik Pagano lige 2437 aktier gratis, i stedet for alle dem han solgte.

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #57

                                    ja, det er svært at tabe penge på den transaktion;-)

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      Klarussen
                                      wrote on sidst redigeret af
                                      #58

                                      Paganos`s doing well...

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bikube
                                        wrote on sidst redigeret af
                                        #59

                                        Hvis han havde ventet 2 dage, kunne han have fået 836 000 kr mere.

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #60

                                          Et lidt andet perspektiv på den påståede grådighed findes på side 109-111 i årsrapporten. Samlet set koster løn, bonus, resticted stocks mv til bestyrelsen og Excecutive management (8 personer) i 2023 i alt 174 mio dkk eller svarende til under 3 kr pr aktie vi ejer https://ir.genmab.com/static-files/85c13ec9-cebd-4a45-9be1-ecf50a112ca8

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper